Please assess the completion status of the following clinical trial:

Trial Title: Effect of Rosiglitazone on the Vascular Biology of Human Fat Tissue

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Overweight but otherwise in good general health.~2. Age 18 - 55 years.~3. Normal glucose tolerance.~4. Stable weight with BMI (27-44).~5. Stable medication use for the preceding month.~6. BP \< 150/90.~7. Negative pregnancy test (\*HCG), if female and of childbearing potential.~8. Practicing, and willing to continue to practice appropriate contraception throughout the study if a female of childbearing potential.~Exclusion Criteria:~1. Serious medical illness.~2. Pregnancy.~3. Tobacco use within the past 6 months.~4. Prior or current treatment with a thiazolidinedione.~5. Patients who have received an investigational drug in the past 30 days.~6. Use of systemic corticosteroids.~7. Known or suspected allergy to Rosiglitazone or any component of the preparation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Rosiglitazone (Type: EXPERIMENTAL): One 8mg capsule daily for 6 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): One capsule daily for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).